Therefore, the results of our study provide a potential explanation for previously reported discrepancies, and highlight the fact that the interpretation of results regarding IL-17 levels in patients with gastric carcinoma is strongly dependent on the profile of included patients, who should be carefully characterized and evaluated according to the Japanese criteria rather than staged solely based on the TNM classification. This evidence concerns the gene IL17A and gastric carcinoma.